Mangoceuticals, Inc. — Form 8-K Summary
Reporting date: April 19, 2024, with the report filed April 25, 2024. The filing primarily reports a patent acquisition, issuance of Series C preferred stock, and Nasdaq compliance matters. It does not provide a new income statement, balance sheet, or cash-flow statement.
Business Context and Transaction
- The Company acquired patents and patent applications from Intramont Technologies, Inc. relating to prevention of infections, including the common cold, respiratory diseases, HPV, and other orally transmitted diseases.
- The transaction closed April 24, 2024, through the Company’s wholly owned subsidiary, MangoRx IP Holdings, LLC.
- The Company intends to pursue research, development, clinical studies, and efficacy testing for oral products, including dissolvable tablets, lozenges, toothpaste, and mouthwash.
Financial and Capitalization Details
- Total purchase consideration was $20.0 million: 980,000 shares of newly designated 6% Series C Convertible Preferred Stock valued at $19.6 million, plus $400,000 cash.
- Cash payments are scheduled as follows: $200,000 by June 30, 2024; $100,000 by August 31, 2024; and $100,000 by November 30, 2024.
- Each Series C preferred share has an initial $20 stated value, a 6% cumulative dividend rate, and an initial conversion price of $10 per common share. The 980,000 issued shares could convert into a maximum of 1,960,000 common shares, excluding dividends and other adjustments.
- Dividends may be paid in cash, common stock, or in-kind through an increase to stated value, subject to authorization, declaration, and applicable law.
- The Series C preferred stock has a $20-per-share liquidation preference, ranks behind Series B preferred stock, and is redeemable by the Company at stated liquidation preference beginning April 24, 2025.
- The filing does not provide current revenue, net income, operating cash flow, cash balance, gross margin, or debt balances.
Material Changes and Other Terms
- The Company granted Intramont a worldwide, irrevocable, co-exclusive license to use the patents. Intramont must pay the Company royalties equal to 10% of gross worldwide sales of products using the patents, beginning April 24, 2025, with annual payments due within 30 days after each calendar year-end.
- Intramont received a right of first refusal through April 24, 2027, for any proposed sale of the patents.
- The Series C preferred stock generally has no voting rights but includes protective provisions requiring majority approval of the Series C holders for specified adverse amendments or capital-structure actions.
- Conversion is subject to beneficial ownership limits of 4.999%, which may be increased to 9.999% with notice, and a general Nasdaq-related restriction on issuing more than 19.99% of outstanding shares without stockholder approval.
- The issuance was exempt from Securities Act registration under Section 4(a)(2) and/or Regulation D Rule 506. The shares are restricted securities.
Guidance, Outlook, Risks, and Contingencies
- Management expects the patent portfolio to support future oral-product development, but the filing provides no revenue forecast, commercialization timetable, clinical results, or profitability guidance.
- Failure to timely make a cash payment allows a 30-day cure period; thereafter, the Company may purchase a 30-day extension for $15,000 per payment.
- The Company previously reported stockholders’ equity of $1.35 million as of September 30, 2023, below Nasdaq’s $2.5 million continued-listing requirement. It believes the patent transaction and April 4, 2024 financing raised equity above $2.5 million and potentially above $5 million, but expects to evidence compliance in its next periodic report.
- Nasdaq continues to monitor compliance. The Company remains out of compliance with the minimum bid-price requirement and intends to request a further 180-day extension. If necessary, management may pursue a reverse stock split.
- Key risks include patent development and validation, clinical and regulatory uncertainty, future funding needs, dilution from preferred-stock conversion and dividends, required cash payments, and potential Nasdaq delisting.
Investor Verification Checklist
- Verify the final accounting treatment and carrying value of the acquired patents and the Series C preferred stock in the next periodic filing.
- Confirm payment of the scheduled $400,000 cash consideration and any related extension fees.
- Review the Series C Designation for dividend accrual, conversion adjustments, redemption terms, and dilution impact.
- Confirm whether the Company demonstrates Nasdaq stockholders’ equity compliance in its next periodic report.
- Monitor Nasdaq’s response regarding the minimum bid-price extension and any reverse-stock-split action.
- Assess clinical, regulatory, intellectual-property, and commercialization progress for products using the acquired patents.